X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs GSK PHARMA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA GSK PHARMA ASTRAZENECA PHARMA/
GSK PHARMA
 
P/E (TTM) x 117.5 53.7 219.1% View Chart
P/BV x 22.8 10.6 214.1% View Chart
Dividend Yield % 0.0 2.7 -  

Financials

 ASTRAZENECA PHARMA   GSK PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
GSK PHARMA
Mar-18
ASTRAZENECA PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2782,760 46.3%   
Low Rs8832,040 43.3%   
Sales per share (Unadj.) Rs228.4339.0 67.4%  
Earnings per share (Unadj.) Rs10.441.4 25.0%  
Cash flow per share (Unadj.) Rs16.345.9 35.4%  
Dividends per share (Unadj.) Rs035.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs98.8242.9 40.7%  
Shares outstanding (eoy) m25.0084.70 29.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.77.1 66.8%   
Avg P/E ratio x104.257.9 179.9%  
P/CF ratio (eoy) x66.452.3 127.1%  
Price / Book Value ratio x10.99.9 110.7%  
Dividend payout %084.5 0.0%   
Avg Mkt Cap Rs m27,008203,280 13.3%   
No. of employees `0001.4NA-   
Total wages/salary Rs m1,5355,234 29.3%   
Avg. sales/employee Rs Th4,210.9NM-  
Avg. wages/employee Rs Th1,132.2NM-  
Avg. net profit/employee Rs Th191.1NM-  
INCOME DATA
Net Sales Rs m5,71028,715 19.9%  
Other income Rs m123545 22.5%   
Total revenues Rs m5,83329,260 19.9%   
Gross profit Rs m4635,059 9.2%  
Depreciation Rs m147380 38.8%   
Interest Rs m02 0.0%   
Profit before tax Rs m4385,222 8.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0178 0.0%   
Tax Rs m1791,892 9.5%   
Profit after tax Rs m2593,508 7.4%  
Gross profit margin %8.117.6 46.0%  
Effective tax rate %40.836.2 112.7%   
Net profit margin %4.512.2 37.1%  
BALANCE SHEET DATA
Current assets Rs m3,20921,815 14.7%   
Current liabilities Rs m2,07015,999 12.9%   
Net working cap to sales %20.020.3 98.5%  
Current ratio x1.61.4 113.7%  
Inventory Days Days7264 113.8%  
Debtors Days Days3519 186.9%  
Net fixed assets Rs m79012,475 6.3%   
Share capital Rs m50847 5.9%   
"Free" reserves Rs m2,41919,726 12.3%   
Net worth Rs m2,46920,573 12.0%   
Long term debt Rs m06 0.0%   
Total assets Rs m4,60539,475 11.7%  
Interest coverage xNM2,612.0-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.7 170.4%   
Return on assets %5.68.9 63.3%  
Return on equity %10.517.1 61.5%  
Return on capital %17.726.2 67.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m300564 53.1%   
Fx outflow Rs m2,0157,429 27.1%   
Net fx Rs m-1,715-6,865 25.0%   
CASH FLOW
From Operations Rs m884,728 1.9%  
From Investments Rs m-94-1,042 9.0%  
From Financial Activity Rs mNA-3,066 0.0%  
Net Cashflow Rs m-6620 -0.9%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 50.7 147.9%  
Indian inst/Mut Fund % 0.3 10.2 2.9%  
FIIs % 15.7 23.8 66.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 15.4 59.1%  
Shareholders   12,856 102,036 12.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   PLETHICO PHARMA  DIVIS LABORATORIES  FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend; Sensex Ends 495 Points Lower(Closing)

Indian share markets witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)

Apr 9, 2019

It's a matter of time before the stocks catch the fancy of the markets and big investors.

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Apr 22, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS